Cannabinoids in Pain Treatment: An Overview.
Theresa Mallick-Searle, Barbara St Marie
PMID 31036325WHAT IT FOUND
The FDA-approved synthetic THC products in the United States are not approved for pain.
This overview reports mixed, low-quality evidence. A cited Cochrane review concluded benefit may outweigh harm in chronic neuropathic pain.
Key findings
01The FDA-approved synthetic THC products in the United States are not approved for pain management.
02The overview reports that a Cochrane review concluded potential benefit outweighs potential harm for cannabis-based medicines in chronic neuropathic pain. It also reports pain trials are often small, short, and placebo-controlled.
03For opioid-sparing effects, a cited systematic review found robust preclinical evidence but very low-quality evidence from one of nine clinical studies, and the overview calls for higher-quality trials.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
It is a narrative overview, not a systematic review, so the reader cannot see how studies were selected or whether important studies were missed. The pain trials it summarizes are described as small, short, placebo-controlled, and focused on pain scores rather than function. The opioid-sparing conclusion is based on preclinical work and very low-quality clinical evidence. Legal status varies by state and remains illegal under federal law, which can affect employment and access.
The easy way to misread this
Do not read this overview as proof that cannabis relieves pain or reduces opioid use. It reports no original trial results, and the evidence it cites is described as small, placebo-controlled, and very low quality for opioid sparing.